Bristol Halts Development Of Vinflunine In Bladder Cancer

Company is in discussions with FDA regarding novel cytotoxic, but does not expect to file an NDA for bladder cancer; vinflunine program also includes lung and breast cancer studies.

More from Archive

More from Pink Sheet